PHARMAC has announded that febuxostat (Adenuric) will be funded for treatment-resistant gout through an agreement with Te Arai BioFarma. Febuxostat funding will be subject to Special Authority criteria in the community and restrictions in DHB hospitals.

Febuxostat tablets (Adenuric) will be listed in Section B and in Part II of Section H (the Hospital Medicines List) of the Pharmaceutical Schedule from 1 June 2014.

For more details, go to: http://www.pharmac.health.nz/news/notification-2014-05-14-febuxostat/